Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DA030768 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
| George Mason University | OTHER |
| Howard University | OTHER |
Not provided
Not provided
Not provided
STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.
STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Buprenorphine | Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it. |
| |
| No buprenorphine | No buprenorphine |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| buprenorphine | Drug | To provide buprenorphine for 12 months for those who are interested in receiving it. |
|
| Measure | Description | Time Frame |
|---|---|---|
| VL <400 | Blood test for HIV viral load | Month 0 |
| CD4+ cell count | Blood test for HIV CD4+ cell count | Month 0 |
| VL <400 | Blood test for HIV viral load | 6 months |
| CD4+ cell count | Blood test for HIV CD4+ cell count | 6 months |
| VL <400 | Blood test for HIV viral load | 12 months |
| CD4+ cell count | Blood test for HIV CD4+ cell count | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| HIV risk behaviors | Survey for HIV risks | Month 0 |
| HIV risk behaviors | Survey for HIV risks | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Reincarceration | Measure of rearrest and reincarceration | Month 0 |
| Reincarceration | Measure of rearrest and reincarceration | 6 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fredrick Altice, MD | Yale University School of Medicine/AIDS Program | Principal Investigator |
| Faye Taxman, PhD | George Mason University | Principal Investigator |
| William Lawson, MD | Howard University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Howard University | Washington D.C. | District of Columbia | 20060 | United States |
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D009293 | Opioid-Related Disorders |
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D002047 | Buprenorphine |
| D000069479 | Buprenorphine, Naloxone Drug Combination |
| ID | Term |
|---|---|
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
| HIV risk behaviors | Survey for HIV risks | 12 months |
| Retention in HIV care | Survey data for retention | Month 0 |
| Retention in HIV care | Survey data for retention | 6 months |
| Retention in HIV care | Survey data for retention | 12 months |
| Opioid use | Measure of relapse to opioid use | Month 0 |
| Opioid use | Measure of relapse to opioid use | 6 months |
| Opioid use | Measure of relapse to opioid use | 12 months |
| Medically assisted therapy retention | Measure of length of time on Methadone or Buprenorphine | Month 0 |
| Medically assisted therapy retention | Measure of length of time on Methadone or Buprenorphine | 6 months |
| Medically assisted therapy retention | Measure of length of time on Methadone or Buprenorphine | 12 months |
| Reincarceration | Measure of rearrest and reincarceration | 12 months |
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D000079524 | Narcotic-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D006572 |
| Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D009270 | Naloxone |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |